Gustavo Rivero, MD

Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.

Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.

Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.

Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.

An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.

Gustavo Rivero, MD, discusses evolving therapies for patients with acute myeloid leukemia with monocytic differentiation.